(Reuters) -The European Medicines Agency said on Friday its committee has recommended expanding the use of Danish drugmaker Novo Nordisk’s weight loss drug in adolescents aged 12...
Revenue is expected to grow 17.80% this year and another 13.50% next year. Earnings are estimated to increase by 32.70% this year and an additional 10.90% next year.
Dos and don’ts on how to handle a gold rush
EU attempting to revive Iran nuclear deal with market staying pessimistic Crude prices could rebound from oversold conditions but stay off 2022 highs Both Iran, US likely looking...
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Buy | Buy | Strong Buy | Strong Buy |
| Technical Indicators | Strong Sell | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Summary | Strong Sell | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 0.14 | 0.14 | 0.12 | 0.00 | 0.00% | 248.91K | Sydney | |||
| 4.88 | 4.96 | 4.82 | +0.050 | +1.04% | 1.60M | Sydney | |||
| 13.49 | 13.63 | 13.35 | -0.03 | -0.22% | 509.63K | Sydney | |||
| 0.155 | 0.155 | 0.147 | +0.005 | +3.33% | 2.65M | Sydney | |||
| 0.205 | 0.215 | 0.20 | 0.00 | 0.00% | 52.52M | Sydney | |||
| 65.14 | 65.25 | 64.36 | +0.54 | +0.84% | 357.58K | Sydney | |||
| 0.009 | 0.009 | 0.009 | 0.00 | 0.00% | 0.00 | Sydney | |||
| 0.89 | 0.915 | 0.885 | -0.005 | -0.56% | 934.95K | Sydney | |||
| 38.08 | 38.34 | 37.72 | -0.03 | -0.08% | 335.69K | Sydney | |||
| 0.024 | 0.024 | 0.022 | 0.00 | 0.00% | 0.00 | Sydney | |||
| 2.69 | 2.71 | 2.69 | 0.00 | 0.00% | 0.00 | Sydney | |||
| 0.41 | 0.41 | 0.395 | -0.005 | -1.20% | 46.89K | Sydney | |||
| 0.28 | 0.295 | 0.265 | +0.010 | +3.70% | 121.47K | Sydney | |||
| 1.72 | 1.745 | 1.70 | +0.020 | +1.18% | 93.59K | Sydney | |||
| 13.07 | 13.17 | 13.015 | +0.040 | +0.31% | 2.29M | Sydney |